Perrigo Licenses Antihistamine Levocetirizine, “Prime” Switch Candidate
This article was originally published in The Tan Sheet
Perrigo's licensing agreement with Synthon Pharmaceuticals to market a generic of UCB's antihistamine Xyzal brings the private labeler a "prime example" of an Rx-to-OTC switch candidate. Switch is a "likely scenario" for the allergy drug, Perrigo maintains
You may also be interested in...
Johnson & Johnson's extensive recall of leading brand name analgesics spurred sales growth for Perrigo's private-label products in the category during the firm's most recent earnings period
Insurers are increasingly encouraging members to use over-the-counter drugs in place of more expensive prescription options by expanding coverage plans, offering coupons or paying for a member's first supply of an OTC drug. The growing trend reflects a push to contain rising health care costs
Schering-Plough's post-approval commitments for OTC Claritin include submitting to FDA reported cases of the birth defect hypospadia following maternal ingestion of loratadine, the company said